Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease with Option for up to an Additional Two Years of Treatment and an Open-Label Extension with Active Study Treatment

Next Previous
X
Search
Trial Profile

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease with Option for up to an Additional Two Years of Treatment and an Open-Label Extension with Active Study Treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SCarlet RoAD
  • Sponsors Roche

    • Most Recent Events

    • 04 Aug 2022 Results comparing ARIA-E severity scales and effects of treatment management thresholds among two phase III clinical studies: SCarlet RoAD and Marguerite RoAD presented at the Alzheimer's Association International Conference 2022
    • 04 Aug 2022 Results investigating the pharmacodynamic effects of gantenerumab on plasma markers for amyloid and tau during NCT01224106 and NCT02051608 (both double-blind and OLE), presented at the Alzheimer's Association International Conference 2022
    • 04 Aug 2022 Results presented at the Alzheimer's Association International Conference 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top